These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 21978311)

  • 1. Commentary on Turner et al. (2011): Significant global scale-up of harm reduction interventions and pragmatic research approaches needed to prevent hepatitis C transmission.
    Day C; Topp L
    Addiction; 2011 Nov; 106(11):1989-90. PubMed ID: 21978311
    [No Abstract]   [Full Text] [Related]  

  • 2. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence.
    Turner KM; Hutchinson S; Vickerman P; Hope V; Craine N; Palmateer N; May M; Taylor A; De Angelis D; Cameron S; Parry J; Lyons M; Goldberg D; Allen E; Hickman M
    Addiction; 2011 Nov; 106(11):1978-88. PubMed ID: 21615585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harm Reduction Coverage and Hepatitis C Incidence: Findings From a Cohort of People Who Inject Drugs.
    Minoyan N; Artenie AA; Zang G; Jutras-Aswad D; Turcotte MÈ; Bruneau J
    Am J Prev Med; 2020 Jun; 58(6):845-853. PubMed ID: 32444003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Commentary on Fraser et al. (2018): Evidence base for harm reduction services-the urban-rural divide.
    Lancaster KE; Malvestutto CD; Miller WC; Go VF
    Addiction; 2018 Jan; 113(1):183-184. PubMed ID: 29226535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is point of access to needles and syringes related to needle sharing? Comparing data collected from pharmacies and needle and syringe programs in south-east Sydney.
    Bryant J; Topp L; Hopwood M; Iversen J; Treloar C; Maher L
    Drug Alcohol Rev; 2010 Jul; 29(4):364-70. PubMed ID: 20636651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Commentary on Vickerman et al. (2012): Reducing hepatitis C virus among injection drug users through harm reduction programs.
    Smith-Spangler CM; Asch SM
    Addiction; 2012 Nov; 107(11):1996-7. PubMed ID: 23039752
    [No Abstract]   [Full Text] [Related]  

  • 7. Injecting drug use in India and the need for policy and program change.
    Panda S; Kumar MS
    Int J Drug Policy; 2016 Nov; 37():115-116. PubMed ID: 27771524
    [No Abstract]   [Full Text] [Related]  

  • 8. Deadly disregard: government refusal to implement evidence-based measures to prevent HIV and hepatitis C virus infections in prisons.
    Elliott R
    CMAJ; 2007 Jul; 177(3):262-4. PubMed ID: 17664450
    [No Abstract]   [Full Text] [Related]  

  • 9. HCV rate high in Baltimore.
    AIDS Patient Care STDS; 1999 Sep; 13(9):571. PubMed ID: 10813045
    [No Abstract]   [Full Text] [Related]  

  • 10. Hepatitis C and HIV incidence and harm reduction program use in a conflict setting: an observational cohort of injecting drug users in Kabul, Afghanistan.
    Todd CS; Nasir A; Stanekzai MR; Fiekert K; Sipsma HL; Vlahov D; Strathdee SA
    Harm Reduct J; 2015 Oct; 12():22. PubMed ID: 26472126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender differences in needle sharing behaviour patterns.
    Smyth B; Keenan E; Dorman A; O'Connor JJ
    Addiction; 1994 Jan; 89(1):96-7. PubMed ID: 8148751
    [No Abstract]   [Full Text] [Related]  

  • 12. Trends in sources and sharing of needles among people who inject drugs, San Francisco, 2005-2012.
    Kim NJ; Jin H; McFarland W; Raymond HF
    Int J Drug Policy; 2015 Dec; 26(12):1238-43. PubMed ID: 26365768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland.
    Allen EJ; Palmateer NE; Hutchinson SJ; Cameron S; Goldberg DJ; Taylor A
    Int J Drug Policy; 2012 Sep; 23(5):346-52. PubMed ID: 22940142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus serosorting in people who inject drugs: sorting out the details.
    Kim AY; Page K
    J Infect Dis; 2013 Dec; 208(12):1929-31. PubMed ID: 24136791
    [No Abstract]   [Full Text] [Related]  

  • 15. [Hepatitis C transmission].
    Diago M
    Rev Esp Enferm Dig; 2007 Jun; 99(6):309-14. PubMed ID: 17883292
    [No Abstract]   [Full Text] [Related]  

  • 16. The hepatitis C epidemic, shall we remain silent?
    Paredes A; Zweben JE
    J Addict Dis; 2001; 20(1):1-7. PubMed ID: 11286427
    [No Abstract]   [Full Text] [Related]  

  • 17. The physical health of people who inject drugs: complexities, challenges, and continuity.
    Cornford C; Close H
    Br J Gen Pract; 2016 Jun; 66(647):286-7. PubMed ID: 27231287
    [No Abstract]   [Full Text] [Related]  

  • 18. The furthest left behind: the urgent need to scale up harm reduction in prisons.
    Sander G; Murphy F
    Int J Prison Health; 2017 Sep; 13(3-4):185-191. PubMed ID: 28914120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacy Access to Sterile Injection Supplies for People Who Inject Drugs.
    Barnett BS; Morris NP
    JAMA Intern Med; 2021 Feb; 181(2):153-154. PubMed ID: 33252623
    [No Abstract]   [Full Text] [Related]  

  • 20. Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study.
    Ruan Y; Qin G; Yin L; Chen K; Qian HZ; Hao C; Liang S; Zhu J; Xing H; Hong K; Shao Y
    AIDS; 2007 Dec; 21 Suppl 8():S39-46. PubMed ID: 18172390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.